Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Melanoma

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    September 2024
  1. LI ZJ, He B, Domenichini A, Satiaputra J, et al
    Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models.
    J Clin Invest. 2024;134:e179860.
    PubMed     Abstract available


  2. VERMA S, Budhu S, Serganova I, Dong L, et al
    Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.
    J Clin Invest. 2024;134:e177606.
    PubMed     Abstract available


    May 2024
  3. CONWAY JR, Gillani R, Crowdis J, Reardon B, et al
    Somatic structural variants drive distinct modes of oncogenesis in melanoma.
    J Clin Invest. 2024 May 14:e177270. doi: 10.1172/JCI177270.
    PubMed     Abstract available


  4. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
    J Clin Invest. 2024;134:e181575.
    PubMed    


    April 2024
  5. ZHAN Y, Guo J, Yang W, Goncalves C, et al
    MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
    J Clin Invest. 2024;134:e181338.
    PubMed    


    February 2024
  6. WU M, Hanly A, Gibson F, Fisher R, et al
    The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
    J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063.
    PubMed     Abstract available


    December 2023
  7. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
    Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
    J Clin Invest. 2023;133:e177489.
    PubMed    


    November 2023
  8. AJITH A, Mamouni K, Horuzsko DD, Musa A, et al
    Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
    J Clin Invest. 2023;133:e167951.
    PubMed     Abstract available


    August 2023
  9. HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al
    Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response with MAPK-targeted therapy in melanoma.
    J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644.
    PubMed     Abstract available


    July 2023
  10. OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al
    Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    J Clin Invest. 2023;133:e170762.
    PubMed     Abstract available


    January 2023
  11. HUUHTANEN J, Kasanen HH, Peltola K, Lonnberg T, et al
    Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.
    J Clin Invest. 2023 Jan 31:e164809. doi: 10.1172/JCI164809.
    PubMed     Abstract available


    July 2022
  12. HICKMAN A, Koetsier J, Kurtanich T, Nielsen MC, et al
    LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    June 2022
  13. HUANG H, Nie C, Liu XF, Song B, et al
    Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
    J Clin Invest. 2022 Jun 21. pii: 157726. doi: 10.1172/JCI157726.
    PubMed     Abstract available


    May 2022
  14. PAL S, Perrien DS, Yumoto T, Faccio R, et al
    The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cells homing to bone.
    J Clin Invest. 2022 May 3. pii: 157340. doi: 10.1172/JCI157340.
    PubMed     Abstract available


  15. PAGLIANO O, Morrison RM, Chauvin JM, Banerjee H, et al
    Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    April 2022
  16. CHEN D, Le SB, Hutchinson TE, Calinescu AA, et al
    Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.
    J Clin Invest. 2022;132.
    PubMed     Abstract available


    January 2022
  17. XU J, Su SM, Zhang X, Chan UI, et al
    ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of non-apoptotic phosphatidylserine.
    J Clin Invest. 2022 Jan 13. pii: 149473. doi: 10.1172/JCI149473.
    PubMed     Abstract available


    November 2021
  18. KRISTENSEN NP, Heeke C, Tvingsholm SA, Borch A, et al
    Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma.
    J Clin Invest. 2021 Nov 23. pii: 150535. doi: 10.1172/JCI150535.
    PubMed     Abstract available


  19. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    October 2021
  20. PERI A, Greenstein E, Alon M, Pai JA, et al
    Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  21. CHAKRABORTY B, Byemerwa J, Shepherd JH, Haines CN, et al
    Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
    J Clin Invest. 2021 Oct 12. pii: 151347. doi: 10.1172/JCI151347.
    PubMed     Abstract available


    August 2021
  22. VEATCH JR, Singhi N, Srivastava S, Szeto JL, et al
    A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


    May 2021
  23. GIBLIN W, Bringman-Rodenbarger L, Guo AH, Kumar S, et al
    The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.
    J Clin Invest. 2021 May 4. pii: 138926. doi: 10.1172/JCI138926.
    PubMed     Abstract available


    April 2021
  24. KIM YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, et al
    Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy.
    J Clin Invest. 2021 Apr 29. pii: 145859. doi: 10.1172/JCI145859.
    PubMed     Abstract available


    March 2021
  25. WORREDE A, Douglass SM, Weeraratna AT
    The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  26. HEEMSKERK N, Gruijs M, Temming AR, Heineke MH, et al
    Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    J Clin Invest. 2021;131.
    PubMed     Abstract available


  27. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.
    J Clin Invest. 2021 Mar 9. pii: 140752. doi: 10.1172/JCI140752.
    PubMed     Abstract available


    May 2020
  28. LI J, Wang W, Zhang Y, Cieslik M, et al
    Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
    J Clin Invest. 2020;130:2712-2726.
    PubMed     Abstract available


  29. THEIVANTHIRAN B, Evans KS, DeVito NC, Plebanek M, et al
    A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    J Clin Invest. 2020;130:2570-2586.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.